Christian Riedel

Christian Riedel

Senior Forskare
Telefon: +46852483885
Besöksadress: Blickagången 16, 14152 Flemingsberg
Postadress: H7 Medicin, Huddinge, H7 CeRM Riedel, 171 77 Stockholm

Om mig

Forskningsbeskrivning

  • Åldrande, Nnringsberoende signalering, transkription, kromatinbiologi

Artiklar

Alla övriga publikationer

Forskningsbidrag

  • Swedish Research Council
    1 January 2024 - 31 December 2027
    Aging is the biggest risk factor for human morbidity and mortality, caused by damage accumulation and resulting functional decline of the organism over time. Fortunately, aging can be interfered with, and thus detailed mechanistic understanding of the underlying pathways could instruct powerful therapies to extend our healthspan and lifespan. Our research focuses on one of the most powerful aging regulators, the insulin/IGF signaling (IIS) pathway, relaying nutrient scarcity into a transcriptional program that improves stress resistance, slows damage accumulation, and ultimately defers aging. Much of this program is driven by the transcription factor (TF) DAF-16/FOXO, but it has long been thought that also the chromatin landscape could play an important role in its coordination. Indeed, by ATAC-seq we identified vast changes in chromatin accessibility under reduced IIS, and through different approaches we identified four chromatin-associated proteins that either confer or utilize these changes to contribute to the aging-preventive transcriptional outcomes. These include two chromatin-associated proteins that directly bind to DAF-16/FOXO, namely BAF-1 and PQN-51, and two TFs that bind enhancer regions which open up under reduced IIS, LIN-39 and LIN-32. Each of them are essential for reduced IIS to prevent aging but they function through distinct mechanisms of action, and we think that their full understanding will provide exciting new insights into aging prevention.
  • Swedish Cancer Society
    1 January 2024
    Despite many years of intensive research, there is currently a lack of effective treatment options for many types of cancer. It is clear that to be able to cure more forms of cancer, new therapeutic strategies are required. Treatment of cancer is today focused on the cancer cells themselves, but it is now clear that cancer requires interaction between the cancer cells and surrounding cells, which are in themselves healthy but which support the cancer cells. The molecular mechanisms that make up the interaction between cancer cells and surrounding tissue are currently incompletely mapped. A characteristic of most cancer cells is that they carry an abnormal number of chromosomes compared to normal cells, a condition known as aneuploidy. This chromosomal imbalance facilitates the cancer cells' ability to usurp extreme properties, such as uncontrolled growth through cell division. However, aneuploidy also involves a strain on basal cellular mechanisms. New data indicate that such cellular stress leads to the secretion of signaling molecules that can affect surrounding normal cells. In this project, we wish to validate the existence of this communication between cells and investigate whether it is important in tumor diseases. To begin with, we hope to confirm the existence of this new form of communication between cancer cells and their cellular neighbors in the local tissue. If this works, we will map the underlying molecular mechanisms and test whether they are required for cancer cell survival and the ability to form tumors. If so, manipulation of these communication mechanisms may represent a new strategy for treating cancer.
  • A new mechanism by which mitochondria modulate the outcomes of reduced insulin/IGF-like signaling and slow down the aging process
    Novo Nordisk Foundation
    1 January 2023 - 31 December 2024
  • A new mechanism by which mitochondria modulate the outcomes of reduced insulin/IGF-like signaling and slow down the aging process
    Novo Nordisk Foundation
    1 January 2022 - 31 December 2022
  • Swedish Cancer Society
    1 January 2021
    Despite many years of intensive research, there is currently a lack of effective treatment options for many types of cancer. It is clear that to be able to cure more forms of cancer, new therapeutic strategies are required. Treatment of cancer is today focused on the cancer cells themselves, but it is now clear that cancer requires interaction between the cancer cells and surrounding cells, which are in themselves healthy but which support the cancer cells. The molecular mechanisms that make up the interaction between cancer cells and surrounding tissue are currently incompletely mapped. A characteristic of most cancer cells is that they carry an abnormal number of chromosomes compared to normal cells, a condition known as aneuploidy. This chromosomal imbalance facilitates the cancer cells' ability to usurp extreme properties, such as uncontrolled growth through cell division. However, aneuploidy also involves a strain on basal cellular mechanisms. New data indicate that such cellular stress leads to the secretion of signaling molecules that can affect surrounding normal cells. In this project, we wish to validate the existence of this communication between cells and investigate whether it is important in tumor diseases. To begin with, we hope to confirm the existence of this new form of communication between cancer cells and their cellular neighbors in the local tissue. If this works, we will map the underlying molecular mechanisms and test whether they are required for cancer cell survival and the ability to form tumors. If so, manipulation of these communication mechanisms may represent a new strategy for treating cancer.
  • Swedish Research Council
    1 January 2020 - 31 December 2023
  • Swedish Research Council
    1 January 2016 - 31 December 2019
  • Molecular mechanisms of longevity control
    International Human Frontier Science Program Organization
    1 May 2008 - 30 April 2011

Anställningar

  • Senior Forskare, Medicin, Huddinge, Karolinska Institutet, 2024-
  • Associate Professor, Department of Molecular Biosciences, The Wenner-Gren Institute, Stockholm University, 2024-
  • Professor, Chair of Nutritional Physiology, Faculty of Lifesciences, University of Bayreuth, 2023-2024
  • Assistant Professor, European Research Institute for the Biology of Ageing, University Medical Center Groningen, 2013-2015
  • Postdoctoral Fellow, Dept of Molecular Biology, Massachusetts General Hospital, 2007-2012

Examina och utbildning

  • Molecular Biology, Research Institute of Molecular Pathology, 2006
  • Biochemistry, University of Tübingen, 2001

Nyheter från KI

Kalenderhändelser från KI